Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.42 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.42 |
| ▸ | RRM1 | P23921 | 1/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.37 |
| ▸ | MASP2 | O00187 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.35 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17833042 | 0.96 | GLP1R (0.48) | GLP1RDPP7GNAI3GNAO1GNAI1 | |
| SCHEMBL19707982 | 0.92 | GLP1R (0.40) | GLP1RDPP7GNAI3GNAO1GNAI1 | |
| SCHEMBL18251533 | 0.89 | GLP1R (0.46) | GLP1RSIRT2 | |
| SCHEMBL21568724 | 0.88 | GLP1R (0.38) | GLP1RDPP7GNAI3GNAO1GNAI1 | |
| SCHEMBL30407618 | 0.84 | TDP1 (0.38) | GLP1RDPP7GNAI3GNAO1GNAI1 | |
| SCHEMBL30407749 | 0.84 | TDP1 (0.38) | GLP1RDPP7GNAI3GNAO1GNAI1 | |
| SCHEMBL30407180 | 0.83 | TDP1 (0.39) | GLP1RDPP7GNAI3GNAO1GNAI1 | |
| SCHEMBL30407214 | 0.82 | MEN1 (0.35) | GLP1RMASP2F2 | |
| SCHEMBL25680409 | 0.81 | DPP7 (0.34) | GLP1RDPP7GNAI3GNAO1GNAI1 | |
| SCHEMBL1953200 | 0.79 | OTC (0.49) | GLP1RNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4104865-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-3468996-B1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2022-05-04 | — | — | EP | disclosed |
| US-20190142941-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2019-05-16 | — | — | US | disclosed |
| WO-2017214282-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20170355769-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2017-12-14 | — | — | US | disclosed |
| WO-2017214335-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017214462-A2 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20160339117-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC. (US) | 2016-11-24 | — | — | US | disclosed |
| WO-2016094509-A1 | BCL XL INHIBITORY COMPOUNDS HAVING LOW CELL PERMEABILITY AND ANTIBODY DRUG CONJUGATES INCLUDING THE SAME | ABBVIE INC. (US) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355769-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | HRH3, H1-3, CD274 | GLP1R 1569/4885DPP7 1862/4885GNAI3 1779/4885 |
| US-20160339117-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | GLP1R 808/4885DPP7 2067/4885GNAI3 2976/4885 |
| US-20190142941-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | GLP1R 808/4885DPP7 2067/4885GNAI3 2976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.